Celldex Therapeutics, Inc. (CLDX) financial statements (2021 and earlier)

Company profile

Business Address 53 FRONTAGE ROAD
HAMPTON, NJ 08827
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6494139190290201
Cash and cash equivalents112440427228
Short-term investments537099147218173
Other undisclosed current assets255654
Total current assets:6799145196295205
Noncurrent Assets
Operating lease, right-of-use asset3
Property, plant and equipment4610131111
Intangible assets, net (including goodwill)49491591723031
Goodwill  919199
Intangible assets, net (excluding goodwill)494968812122
Other noncurrent assets022212
Total noncurrent assets:56571711884343
TOTAL ASSETS:123156316383338248
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8821302626
Accounts payable112223
Accrued liabilities6719292419
Employee-related liabilities     4
Debt2     
Other liabilities257543
Other undisclosed current liabilities     (4)
Total current liabilities:121328353024
Noncurrent Liabilities
Long-term debt and lease obligation2     
Operating lease, liability2
Liabilities, other than long-term debt161952831712
Other liabilities161952831712
Total noncurrent liabilities:171952831712
Total liabilities:2932791184736
Stockholders' equity
Stockholders' equity attributable to parent94124236265290212
Common stock000000
Additional paid in capital1,1051,0841,046982879673
Accumulated other comprehensive income333323
Accumulated deficit(1,013)(962)(813)(719)(591)(464)
Total stockholders' equity:94124236265290212
TOTAL LIABILITIES AND EQUITY:123156316383338248

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues41013754
Cost of revenue(0)(60) (3)(1) 
Cost of goods and services sold(0)(1)    
Gross profit:3(51)13444
Operating expenses(58)(106)(135)(137)(134)(126)
Other undisclosed operating income  1  0
Operating loss:(55)(156)(122)(133)(130)(122)
Loss from continuing operations before equity method investments, income taxes:(55)(156)(122)(133)(130)(122)
Other undisclosed income from continuing operations before income taxes444   
Loss from continuing operations before income taxes:(51)(152)(117)(133)(130)(122)
Income tax benefit 124   
Net loss attributable to parent:(51)(151)(93)(133)(130)(122)
Other undisclosed net income available to common stockholders, basic   424
Net loss available to common stockholders, diluted:(51)(151)(93)(129)(127)(118)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(51)(151)(93)(133)(130)(122)
Other comprehensive loss     (0)
Comprehensive loss:(51)(151)(93)(133)(130)(123)
Other undisclosed comprehensive income, net of tax, attributable to parent000524
Comprehensive loss, net of tax, attributable to parent:(51)(151)(93)(128)(127)(118)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: